Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation

Heart

Volumn 93, Issue 4, 2007, Pages 495-499

  Varughese, George I ^a   Patel, Jeetesh V ^a   Tomson, Joseph ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PADGEM PROTEIN; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS;

AGED; ATRIAL FIBRILLATION; BLOOD PRESSURE; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; P-SELECTIN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 34247367973     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.099374     Document Type: Article

References (33)

1. Lip GYH. Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension 2003;41:199-200.
2. Virchow R. Phlogose und Thrombose in Gerasssystem. In: Virchow R, ed. Gesammelte Abhandlungen zur Wissenchaftichen Medicin. Frankfurt, Germany, Von Meidinger Sohn 1856:458-636.
3. Varughese GI, Lip GY. Is hypertension a prothrombotic state? Curr Hypertens Rep 2005;7:168-73.
4. Lip GY, Boos C. Antithrombotic therapy for atrial fibrillation. Heart 2006;92:155-61.
5. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32:803-8.
6. Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical prcictice. Pathophysiol Haemost Thromb 2003-2004;33:282-9.
7. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5.
8. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002;106:1962-7.
9. Patel JV, Lim HS, Nadar S, et al. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006;24:117-21.
10. Lim HS, Lip GY, Blann AD. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 2004;89:5377-81.
11. Lip GY, Lowe GD, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995;73:527-33.
12. Lip GY, Pearce LA, Chin BS, et al. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart 2005;91:759-63.
13. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990;6:217-46.
14. Lip GY, Blann AD. von Wilebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65.
15. Luscher TF. The endothelium and cardiovascular disease - a complex relation. N Engl J Med 1994;330:1081-3.
16. Heppell RM, Berkin KE, McLenachan JM, et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997;77:407-11.
17. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001;37:1436-42.
18. Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000;140:777-84.
19. Spencer CG, Gurney D, Blann AD, et al. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2002;40:61-6.
20. Blann AD, McCollum CN, Lip GY. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinol 2002;13:513-18.
21. Alli C, Mariotti G, Avanzini F, et al. Studio sulla Pressione Arteriosa nell'Anziano(SPAA). Long-term prognostic impact of repeated measurements over 1 year of pulse pressure and systolic blood pressure in the elderly. J Hum Hypertens 2005;19:355-63.
22. Beevers DG. Epidemiological, pathophysiological and clinical significance of systolic, diastolic and pulse pressure. J Hum Hypertens 2004;18:531-3.
23. Lip GYH, Frison L, Grind M. The effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2006 (In press).
24. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996;93:11877-82.
25. Blann AD, Lip GY, Beevers DG, et al. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997;77:1077-80.
26. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997;77:1081-5.
27. Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group on behalf of the ACTIVE investigators; Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
28. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvafvular atrial fibrillation. Heart Rhythm 2005;2:525-9.
29. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000;31:828-33.
30. Kamath S, Blann AD, Caine GJ, et al. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 2002;33:1237-42.
31. Li-Saw-Hee FL, Blann AD, Lip GY. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am J Cardiol 2000;86:795-7, A9.
32. Boos G, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006;12:1623-35.
33. Nadar SK, Tayebjee MH, Messerli F, et al. Target organ damage in hypertension: pathophysiology and implications for drug therapy. Curr Pharm Des 2006;12:1581-92.